अApnaFunda
Menu

FDC LIMITED (FDC)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.67 / 100
Profitability 59Growth 42Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.46 / 100
Price 81Earnings 40FII/DII 16
Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹394.2 latest close · −9.1% over the last 90 sessions

₹350₹400Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹350₹400Jul 3Sep 4Nov 9

₹394.2 month-end · −4.9% over 12 months

₹350₹400Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹350₹400Nov '25May '26Nov '26

₹394.2 month-end · +0.1% over 3 years

₹300₹400₹500Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹300₹400₹500Nov '23May '25Nov '26

₹394.2 month-end · +139.3% since Jan '19

₹200₹400Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹200₹400Jan '19Dec '22Nov '26

52-week range ₹312.95 to ₹466.85 · 1-year volatility 30.1%

Was the rally earned?

-5%share price, 1 yearRoughly flat
  • The share price was roughly flat over 1 year (-5%).
  • The share count barely moved.
Net profit growth: +8 pts. Points of the price return explained by net profit growing (or shrinking).+8 ptsNet profit growthP/E change: −13 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−13 ptsP/E changeShare price: −5%−5%Share priceNet profit growth: +8 pts. Points of the price return explained by net profit growing (or shrinking).+8ProfitP/E change: −13 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−13P/EShare price: −5%−5%Share price
Net profit growth+8 ptsNet profit rose about 9%, which lifts the price.
P/E change-13 ptsThe P/E fell from 25.1x to 21.9x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+0%share price, 3 yearsRoughly flat
  • The share price was roughly flat over 3 years (+0%).
  • The share count barely moved.
Net profit growth: +41 pts. Points of the price return explained by net profit growing (or shrinking).+41 ptsNet profit growthP/E change: −43 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−43 ptsP/E changeShare count change: +2 pts. Points of the price return explained by the share count changing. More shares count against the price.+2 ptsShare count changeShare price: 0%0%Share priceNet profit growth: +41 pts. Points of the price return explained by net profit growing (or shrinking).+41ProfitP/E change: −43 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−43P/EShare count change: +2 pts. Points of the price return explained by the share count changing. More shares count against the price.+2SharesShare price: 0%0%Share price
Net profit growth+41 ptsNet profit growth over the period.
P/E change-43 ptsThe P/E fell from 33.6x to 21.9x, which lowers the price.
Share count change+2 ptsShare count was little changed. More shares would count against the price.
+38%share price, 5 yearsMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 16.0x to 21.9x); per-share earnings added 1 point.
  • The share count fell 3%.
Net profit growth: −3 pts. Points of the price return explained by net profit growing (or shrinking).−3 ptsNet profit growthP/E change: +38 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+38 ptsP/E changeShare count change: +4 pts. Points of the price return explained by the share count changing. More shares count against the price.+4 ptsShare count changeShare price: +38%+38%Share priceNet profit growth: −3 pts. Points of the price return explained by net profit growing (or shrinking).−3ProfitP/E change: +38 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+38P/EShare count change: +4 pts. Points of the price return explained by the share count changing. More shares count against the price.+4SharesShare price: +38%+38%Share price
Net profit growth-3 ptsNet profit fell about 3%, which lowers the price.
P/E change+38 ptsThe P/E rose from 16.0x to 21.9x, which lifts the price.
Share count change+4 ptsShare count fell 3%, which lifts the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-47.6%not yet recovered
1-year volatility30.1%annualised
Beta vs sector index0.743-year daily, correlation 0.36
Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%2020202120222023202420252026−47.6% 0%−20%−40%2020202220242026−47.6%
Largest drawdowns

-47.6% (2024-09 peak to 2026-03 low, not yet recovered)

-39.6% (2021-06 peak to 2022-06 low, recovered 2023-08)

-31.5% (2020-02 peak to 2020-03 low, recovered 2020-06)

Most recent volume spikes

2026-10-29: 5.9x the 50-day median, price +0.2% that day

2026-10-28: 16.2x the 50-day median, price +6.4% that day

2026-08-05: 11.9x the 50-day median, price -3.8% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

21.9xP/E todayWithin its usual range
Against its own history46th percentile
CheapestMedian 23.2xDearest

Usual range 16.7x to 30.8x since 2019-01.

Against Health Technology21.9x vs 37.0x
This company
21.9x
Sector median
37.0x

41% below the Health Technology median.

13.8x23.7x33.6x43.5xJan '19Aug '20Mar '22Oct '23May '25Nov '2613.8x23.7x33.6x43.5xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE54thflat vs a year ago
  • Op. margin63rd▼ 3 pts vs a year ago
  • Revenue growth28th▼ 4 pts vs a year ago
  • EPS growth52nd▲ 25 pts vs a year ago
  • Debt/equity ↓93rdflat vs a year ago
  • Cash cycle ↓70th▲ 7 pts vs a year ago
  • P/E ↓75th▲ 9 pts vs a year ago
  • 12M momentum34th▼ 13 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~18%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 25.3x, a holder earning 12%/yr needs earnings to grow about 18.0%/yr for 10 years, then trade at 15x.

Delivered8.8%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+9.2 ptsimplied minus delivered
Rank346thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%11%22% Jan 2019Nov 2026 0%11%22% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x19.6%20.7%21.7%
15x16.9%18.0%19.1%
20x13.6%14.7%15.7%

Drag a slider to test other assumptions

Implied: 18.0%/yr

Looking back

  • Jan 2020Price implied 16%/yr; EPS has since grown 9%/yr (7.0 yrs)
  • Jan 2021Price implied 18%/yr; EPS has since grown 4%/yr (6.0 yrs)
  • Jan 2022Price implied 17%/yr; EPS has since grown −0%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹394.20
P/E
21.9x
ROCE
15.0%
Market Cap
₹6418 cr
Revenue (TTM)
₹2191 cr
P/S
2.9x
P/B
2.6x
ROE
11.8%
Operating Margin
21.0%
Debt / Equity
0.0x
Promoter Holding
69.7%
12M Momentum
-4.9%

52-week range

₹312.95₹466.85
53% of the way from its 52-week low to its high

Price risk

1Y volatility
30.1%
Beta vs sector
1-year daily
0.73

Balance sheet & cash

Interest cover
operating profit ÷ interest
79.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.87x
Share count, 1Y
unchanged

Are profits backed by cash?

6 of 7checks within range1 near a threshold
Other income reliance31%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 30.6%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.87xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.87x (cash from operations ₹739 cr, net profit ₹853 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+4 daysWithin range

Debtor days are above the median of the previous three fiscal years by 4 days (26 vs 22). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress10% of fixed assetsWithin range

Capital work-in-progress is 10% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+3 days / 2 yrsWithin range

Days payable changed by +3 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs trimmed 1.8 pts; FIIs trimmed 1.0 pts.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters69.7%69.7%0.0 pts
FIIs2.4%1.4%-1.0 pts
DIIs8.1%6.3%-1.8 pts
Public and others19.8%22.6%+2.8 pts

Number of shareholders

55,045shareholders-3% since Sep '23
51k53k55k57k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 56,928
Dec '23: 55,341
Mar '24: 52,377
Jun '24: 50,634
Sep '24: 55,400
Dec '24: 55,228
Mar '25: 53,880
Jun '25: 54,445
Sep '25: 54,157
Dec '25: 53,788
Mar '26: 52,730
Jun '26: 55,045
 51k53k55k57k Sep '23Sep '24Sep '25Jun '26
Sep '23: 56,928
Dec '23: 55,341
Mar '24: 52,377
Jun '24: 50,634
Sep '24: 55,400
Dec '24: 55,228
Mar '25: 53,880
Jun '25: 54,445
Sep '25: 54,157
Dec '25: 53,788
Mar '26: 52,730
Jun '26: 55,045

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+11.2%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like FDC LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −21% to +40% vs the market, against 0% for all non-financial companies in the same months.
  • The gap against the base rate (+11.2%, 80% range −3.4% to +20.2%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
DEEPAKNTR · Nov 2024: −45.0% vs market
TVTODAY · Feb 2022: −43.6% vs market
ZENSARTECH · Jul 2025: −38.7% vs market
INDNIPPON · Aug 2020: −34.8% vs market
BAJAJCON · Aug 2023: −30.2% vs market
HONDAPOWER · Feb 2020: −29.6% vs market
MOIL · Aug 2020: −29.0% vs market
ADVENZYMES · Apr 2024: −28.7% vs market
ACC · Dec 2022: −28.7% vs market
NOCIL · Dec 2023: −24.2% vs market
BALMLAWRIE · May 2020: −22.4% vs market
FINCABLES · May 2021: −22.3% vs market
SANDESH · Mar 2020: −21.3% vs market
STARCEMENT · Jul 2020: −20.2% vs market
VESUVIUS · Jan 2020: −19.9% vs market
VINATIORGA · Feb 2025: −18.2% vs market
FINPIPE · May 2021: −14.5% vs market
VSTTILLERS · Jun 2024: −13.9% vs market
INDIGOPNTS · Jul 2025: −12.1% vs market
ARE&M · Mar 2023: −11.6% vs market
LMW · Jun 2024: −3.9% vs market
FLAIR · May 2025: +1.3% vs market
FINEORG · Aug 2025: +4.5% vs market
AJANTPHARM · Jun 2023: +5.5% vs market
ENDURANCE · May 2023: +7.8% vs market
SASKEN · Feb 2020: +14.7% vs market
KRBL · Aug 2022: +17.1% vs market
CERA · Dec 2022: +18.7% vs market
AIAENG · Sep 2022: +20.6% vs market
KSB · Apr 2021: +22.0% vs market
MAYURUNIQ · May 2025: +25.7% vs market
ESCORTS · Jun 2022: +29.6% vs market
JBCHEPHARM · Dec 2022: +32.0% vs market
GPPL · Jan 2023: +34.9% vs market
GLAND · Jun 2025: +35.8% vs market
JYOTHYLAB · Jun 2023: +36.5% vs market
DODLA · Feb 2023: +37.5% vs market
CUMMINSIND · Dec 2021: +41.4% vs market
NUCLEUS · May 2020: +44.4% vs market
VOLTAMP · Mar 2022: +44.7% vs market
TECHNOE · Jul 2022: +45.9% vs market
XCHANGING · Jul 2020: +56.0% vs market
CARBORUNIV · Jan 2021: +60.4% vs market
AVANTIFEED · Apr 2024: +61.5% vs market
KSCL · Apr 2024: +62.6% vs market
RAILTEL · Nov 2022: +86.4% vs market
BDL · Mar 2022: +89.6% vs market
BSE · Dec 2020: +128.7% vs market
NEWGEN · Mar 2023: +137.5% vs market
PERSISTENT · Apr 2020: +168.9% vs market
Similar setups +11.2%All companies 0%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median
+11.2%
All companies' median
0%
Beat the market
58% vs 50%

50 past situations · 50 companies · 35 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
RAILTEL
Communications		 Nov 2022 21x16% +16%−5% +86%
VSTTILLERS
Producer Manufacturing		 Jun 2024 30x18% +47%−2% −14%
ESCORTS
Producer Manufacturing		 Jun 2022 26x16% +18%−24% +30%
GPPL
Transportation		 Jan 2023 21x14% −4%−10% +35%
BALMLAWRIE
Producer Manufacturing		 May 2020 8x16% −22%−25% −22%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
BAJAJCON
Consumer Non-Durables		 Aug 2023 27x21% +59%0% −30%
VESUVIUS
Non-Energy Minerals		 Jan 2020 24x20% −5%−11% −20%
FINCABLES
Producer Manufacturing		 May 2021 17x18% +108%−4% −22%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to FDC LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

ORKLA INDIAORKLAINDIA
Consumer Non-Durables
70%similar
ROCEmarket cap
CELLO WORLDCELLO
Consumer Durables
69%similar
revenuedebt/equity
VINATI ORGANICSVINATIORGA
Process Industries
69%similar
revenueP/E
JYOTHY LABSJYOTHYLAB
Consumer Non-Durables
67%similar
volatilitymarket cap
DHANUKA AGRITECHDHANUKA
Process Industries
65%similar
revenuepromoter holding
CAPLIN POINT LABORATORIESCAPLIPOINT
Health Technology
58%similar
revenuepromoter holding
NATCO PHARMANATCOPHARM
Health Technology
52%similar
EPS growthrevenue growth
ALEMBIC PHARMACEUTICALS LIMITEAPLLTD
Health Technology
50%similar
promoter holdingvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jun '23

  1. OctPriceVolume reached 16.2x its 50-day median on 2026-10-28; price +6.4% that day.
  2. SepPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  3. AugPriceVolume reached 11.9x its 50-day median on 2026-08-05; price -3.8% that day.
  4. JunResultsYear-on-year EPS growth turned positive.
  5. JunPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  6. MayPriceVolume reached 31.7x its 50-day median on 2026-05-27; price +6.5% that day.
  7. MarPriceFell 48% from the Sep 2024 peak to the Mar 2026 low.
  8. MarPriceVolume reached 6.4x its 50-day median on 2026-03-27; price -2.7% that day.
Show 22 earlier events
  1. FebPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
  2. DecPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  3. NovPriceVolume reached 9.0x its 50-day median on 2025-11-06; price -5.7% that day.
  4. SepPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  5. SepPriceVolume reached 67.3x its 50-day median on 2025-09-19; price +2.5% that day.
  6. JunResultsYear-on-year EPS growth turned negative.
  7. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  8. JunDividendStarted paying a dividend (payout 31% of profit).
  9. JunPriceVolume reached 31.2x its 50-day median on 2025-06-16; price +3.0% that day.
  10. FebPriceVolume reached 9.2x its 50-day median on 2025-02-13; price -7.0% that day.
  11. DecPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  12. SepPriceVolume reached 89.3x its 50-day median on 2024-09-12; price +6.0% that day.
  13. JunResultsYear-on-year EPS growth turned positive.
  14. JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
  15. JunPriceVolume reached 8.7x its 50-day median on 2024-06-27; price -1.0% that day.
  16. JanPriceVolume reached 28.2x its 50-day median on 2024-01-03; price +3.3% that day.
  17. DecPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
  18. NovPriceVolume reached 13.4x its 50-day median on 2023-11-22; price +5.2% that day.
  19. AugPriceRegained the 2021-06 peak, 14 months after the low.
  20. AugPriceVolume reached 25.9x its 50-day median on 2023-08-03; price +8.7% that day.
  21. JunResultsRevenue (TTM) reached a new high of ₹1,784 cr.
  22. JunValuationP/E crossed above the 90th percentile of its own history to date (26.5x).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1121.9x₹2191 cr11.8%15.0%0.0x
2026-1021.0x₹2191 cr11.7%15.0%0.0x
2026-0918.9x₹2191 cr11.7%15.0%0.0x
2026-0819.5x₹2171 cr11.3%15.0%0.0x
2026-0723.7x₹2171 cr11.3%15.0%0.0x
2026-0624.5x₹2171 cr11.3%15.0%0.0x
2026-0530.4x₹2078 cr9.5%16.0%0.0x
2026-0427.4x₹2078 cr9.5%16.0%0.0x
2026-0324.1x₹2078 cr9.5%16.0%0.0x
2026-0225.8x₹2077 cr9.9%16.0%0.0x
2026-0127.3x₹2077 cr9.9%16.0%0.0x
2025-1230.5x₹2077 cr9.9%16.0%0.0x
2025-1125.1x₹2118 cr11.8%16.0%0.0x
2025-1027.9x₹2118 cr11.8%16.0%0.0x
2025-0926.8x₹2118 cr11.8%16.0%0.0x
2025-0827.9x₹2108 cr11.7%16.0%0.0x
2025-0729.2x₹2108 cr11.7%16.0%0.0x
2025-0629.7x₹2108 cr11.7%16.0%0.0x
2025-0526.0x₹2078 cr13.1%18.0%0.0x
2025-0425.0x₹2078 cr13.1%18.0%0.0x
2025-0323.4x₹2078 cr13.1%18.0%0.0x
2025-0219.6x₹2072 cr15.1%18.0%0.0x
2025-0124.2x₹2072 cr15.1%18.0%0.0x
2024-1225.7x₹2072 cr15.1%18.0%0.0x
2024-1126.5x₹2044 cr15.0%18.0%0.0x
2024-1028.3x₹2044 cr15.0%18.0%0.0x
2024-0927.9x₹2044 cr15.0%18.0%0.0x
2024-0829.0x₹1943 cr14.5%18.0%0.0x
2024-0727.2x₹1943 cr14.5%18.0%0.0x
2024-0624.6x₹1943 cr14.5%18.0%0.0x
2024-0537.0x₹1784 cr9.8%13.0%0.0x
2024-0438.8x₹1784 cr9.8%13.0%0.0x
2024-0336.3x₹1784 cr9.8%13.0%0.0x
2024-0237.3x₹1784 cr9.8%13.0%0.0x
2024-0135.7x₹1784 cr9.8%13.0%0.0x
2023-1233.9x₹1784 cr9.8%13.0%0.0x
2023-1133.6x₹1784 cr9.8%13.0%0.0x
2023-1031.0x₹1784 cr9.8%13.0%0.0x
2023-0932.8x₹1784 cr9.8%13.0%0.0x
2023-0832.5x₹1784 cr9.8%13.0%0.0x
2023-0729.3x₹1784 cr9.8%13.0%0.0x
2023-0626.5x₹1784 cr9.8%13.0%0.0x
2023-0523.2x₹1525 cr11.0%15.0%0.0x
2023-0423.0x₹1525 cr11.0%15.0%0.0x
2023-0320.0x₹1525 cr11.0%15.0%0.0x
2023-0220.5x₹1525 cr11.0%15.0%0.0x
2023-0120.7x₹1525 cr11.0%15.0%0.0x
2022-1221.1x₹1525 cr11.0%15.0%0.0x
2022-1122.2x₹1525 cr11.0%15.0%0.0x
2022-1024.3x₹1525 cr11.0%15.0%0.0x
2022-0920.6x₹1525 cr11.0%15.0%0.0x
2022-0820.6x₹1525 cr11.0%15.0%0.0x
2022-0719.8x₹1525 cr11.0%15.0%0.0x
2022-0618.6x₹1525 cr11.0%15.0%0.0x
2022-0513.8x₹1331 cr17.4%22.0%0.0x
2022-0415.1x₹1331 cr17.4%22.0%0.0x
2022-0314.4x₹1331 cr17.4%22.0%0.0x
2022-0215.1x₹1331 cr17.4%22.0%0.0x
2022-0116.3x₹1331 cr17.4%22.0%0.0x
2021-1217.0x₹1331 cr17.4%22.0%0.0x
2021-1116.0x₹1331 cr17.4%22.0%0.0x
2021-1017.9x₹1331 cr17.4%22.0%0.0x
2021-0919.6x₹1331 cr17.4%22.0%0.0x
2021-0819.4x₹1331 cr17.4%22.0%0.0x
2021-0720.9x₹1331 cr17.4%22.0%0.0x
2021-0619.8x₹1331 cr17.4%22.0%0.0x
2021-0524.3x₹1341 cr15.5%21.0%0.0x
2021-0421.7x₹1341 cr15.5%21.0%0.0x
2021-0320.4x₹1341 cr15.5%21.0%0.0x
2021-0219.8x₹1341 cr15.5%21.0%0.0x
2021-0120.8x₹1341 cr15.5%21.0%0.0x
2020-1223.7x₹1341 cr15.5%21.0%0.0x
2020-1124.5x₹1341 cr15.5%21.0%0.0x
2020-1024.6x₹1341 cr15.5%21.0%0.0x
2020-0925.4x₹1341 cr15.5%21.0%0.0x
2020-0822.2x₹1341 cr15.5%21.0%0.0x
2020-0721.3x₹1341 cr15.5%21.0%0.0x
2020-0619.9x₹1341 cr15.5%21.0%0.0x
2020-0525.5x₹1089 cr11.8%17.0%0.0x
2020-0425.1x₹1089 cr11.8%17.0%0.0x
2020-0320.0x₹1089 cr11.8%17.0%0.0x
2020-0224.1x₹1089 cr11.8%17.0%0.0x
2020-0124.1x₹1089 cr11.8%17.0%0.0x
2019-1221.7x₹1089 cr11.8%17.0%0.0x
2019-1119.7x₹1089 cr11.8%17.0%0.0x
2019-1018.5x₹1089 cr11.8%17.0%0.0x
2019-0917.9x₹1089 cr11.8%17.0%0.0x
2019-0816.6x₹1089 cr11.8%17.0%0.0x
2019-0715.9x₹1089 cr11.8%17.0%0.0x
2019-0619.2x₹1089 cr11.8%17.0%0.0x
2019-0519.7x₹1074 cr13.6%19.0%0.0x
2019-0417.4x₹1074 cr13.6%19.0%0.0x
2019-0316.7x₹1074 cr13.6%19.0%0.0x
2019-0216.7x₹1074 cr13.6%19.0%0.0x
2019-0116.6x₹1074 cr13.6%19.0%0.0x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback